K. Buser

1.1k total citations · 1 hit paper
17 papers, 875 citations indexed

About

K. Buser is a scholar working on Oncology, Surgery and Reproductive Medicine. According to data from OpenAlex, K. Buser has authored 17 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Surgery and 6 papers in Reproductive Medicine. Recurrent topics in K. Buser's work include Ovarian cancer diagnosis and treatment (6 papers), Nausea and vomiting management (5 papers) and Cancer Treatment and Pharmacology (4 papers). K. Buser is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Nausea and vomiting management (5 papers) and Cancer Treatment and Pharmacology (4 papers). K. Buser collaborates with scholars based in Switzerland, Netherlands and Germany. K. Buser's co-authors include M E van der Burg, W.W. ten Bokkel Huinink, Luca Gianni, Ian G. Kerr, Jan B. Vermorken, Kenneth D. Swenerton, Nicoletta Colombo, Elizabeth A. Eisenhauer, M. Bacchi and R Joss and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

K. Buser

17 papers receiving 831 citations

Hit Papers

European-Canadian randomized trial of paclitaxel in relap... 1994 2026 2004 2015 1994 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
    1994 515 citations Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Buser Switzerland 12 409 323 278 130 111 17 875
M. A. Bookman United States 9 237 0.6× 217 0.7× 316 1.1× 102 0.8× 68 0.6× 15 583
W W ten Bokkel Huinink Netherlands 11 408 1.0× 604 1.9× 558 2.0× 182 1.4× 163 1.5× 20 1.2k
Ida Paris Italy 16 370 0.9× 206 0.6× 241 0.9× 210 1.6× 189 1.7× 72 870
J. J. Kavanagh United States 17 396 1.0× 303 0.9× 545 2.0× 308 2.4× 181 1.6× 50 1.2k
Şennur İlvan Türkiye 19 212 0.5× 206 0.6× 298 1.1× 131 1.0× 153 1.4× 78 1.1k
I Fryatt United Kingdom 14 442 1.1× 261 0.8× 462 1.7× 136 1.0× 316 2.8× 20 1.1k
Suzanne Berlin United States 15 408 1.0× 119 0.4× 451 1.6× 333 2.6× 204 1.8× 37 1.3k
Domenico Sergi Italy 16 359 0.9× 106 0.3× 94 0.3× 178 1.4× 166 1.5× 54 796
Robert F. Asbury United States 16 273 0.7× 124 0.4× 107 0.4× 96 0.7× 150 1.4× 44 653
E. A. Eisenhauer Canada 16 404 1.0× 313 1.0× 504 1.8× 357 2.7× 251 2.3× 31 1.2k

Countries citing papers authored by K. Buser

Since Specialization
Citations

This map shows the geographic impact of K. Buser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Buser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Buser more than expected).

Fields of papers citing papers by K. Buser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Buser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Buser. The network helps show where K. Buser may publish in the future.

Co-authorship network of co-authors of K. Buser

This figure shows the co-authorship network connecting the top 25 collaborators of K. Buser. A scholar is included among the top collaborators of K. Buser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Buser. K. Buser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chappuis, Pierre O., Nicole Bürki, K. Buser, et al.. (2017). Genetic predisposition to breast and ovarian cancer. Bulletin des Médecins Suisses. 98(2122). 682–684. 4 indexed citations
2.
Pichert, Gabriella, et al.. (2002). Evidence-based management options for women at increased breast/ovarian cancer risk. Annals of Oncology. 14(1). 9–19. 42 indexed citations
3.
Berclaz, Gilles, Karl T. Beer, Stefan Aebi, et al.. (2002). Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy. International Journal of Oncology. 20(6). 1313–8. 8 indexed citations
4.
Joncourt, Franziska, et al.. (1998). Multiple Drug Resistance Parameter Expression in Ovarian Cancer. Gynecologic Oncology. 70(2). 176–182. 31 indexed citations
5.
Bois, Andreas du, Hans‐Joachim Lück, K. Buser, et al.. (1997). Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer. 33(3). 379–384. 19 indexed citations
6.
7.
Buser, K., M. Bacchi, Aron Goldhirsch, et al.. (1996). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Annals of Oncology. 7(1). 65–70. 12 indexed citations
8.
Joncourt, Franziska, et al.. (1995). Patterns of Drug Resistance Parameters in Adult Leukemia. Leukemia & lymphoma. 17(1-2). 101–109. 15 indexed citations
9.
Eisenhauer, Elizabeth A., W.W. ten Bokkel Huinink, Kenneth D. Swenerton, et al.. (1994). European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.. Journal of Clinical Oncology. 12(12). 2654–2666. 515 indexed citations breakdown →
10.
Joss, R, M. Bacchi, K. Buser, et al.. (1994). Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Annals of Oncology. 5(3). 253–258. 35 indexed citations
11.
12.
13.
Joss, R, et al.. (1990). The symptomatic control of cytostatic drug-induced emesis. A recent history and review.. PubMed. 26 Suppl 1. S2–8. 25 indexed citations
14.
Buser, K., et al.. (1990). [Ovarian carcinoma: current therapeutic aspects. A review].. PubMed. 120(44). 1617–32. 1 indexed citations
15.
Cerny, T., K. Buser, Jennifer J. Kiser, & R Joss. (1990). [Preventive and therapeutic measures in cytostatic-associated toxicity].. PubMed. 120(37). 1353–62. 1 indexed citations
16.
Joss, R, et al.. (1989). [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].. PubMed. 119(23). 831–4. 2 indexed citations
17.
Goldhirsch, Aron, Richard Greiner, E. Dreher, et al.. (1988). Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer. 62(1). 40–47. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. A. Bookman Breakdown of academic impact, for papers by W W ten Bokkel Huinink Breakdown of academic impact, for papers by Ida Paris Breakdown of academic impact, for papers by J. J. Kavanagh Breakdown of academic impact, for papers by Şennur İlvan Breakdown of academic impact, for papers by I Fryatt Breakdown of academic impact, for papers by Suzanne Berlin Breakdown of academic impact, for papers by Domenico Sergi Breakdown of academic impact, for papers by Robert F. Asbury Breakdown of academic impact, for papers by E. A. Eisenhauer
Rankless by CCL
2026